Oxfendazole: a promising agent for the treatment and control of helminth infections in humans

Armandoe Gonzalez, Ellen E. Codd, John Horton, Hector H. Garcia, Robert H Gilman

Research output: Contribution to journalReview article

Abstract

Introduction: Oxfendazole (methyl [5-(phenylsulphinyl)-1H benzimidazole-2-yl] carbamate) has a particularly long metabolic half-life in ruminants, and its metabolite fenbendazole also has anthelminthic action. A very limited number of drugs are available for the treatment of some zoonotic helminth infections, such as neurocysticercosis and echinococcosis. More recent work has expanded oxfendazole’s nonclinical safety profile and demonstrated its safety and bioavailability in healthy human volunteers, thus advancing the possibility of a new and greatly needed option for antiparasitic treatment of geohelminths and tissue parasites. Areas covered: The present article reviews evidence supporting the safety and efficacy of oxfendazole against both gut and tissue dwelling helminths in animals, as well as more recent safety and pharmacokinetic data supporting its potential for use in human parasitoses. Expert commentary: The pharmacokinetics, safety, and wide spectrum of efficacy of oxfendazole are consistently demonstrated in intestinal helminth infections of animals as well as in tissue dwelling larval cestode and trematode infections in diverse animal species. Now supported by first-in-human safety and pharmacokinetic data, oxfendazole becomes a promising alternative to the limited portfolio of antiparasitic drugs available to treat helminthic diseases of humans.

Original languageEnglish (US)
Pages (from-to)51-56
Number of pages6
JournalExpert Review of Anti-Infective Therapy
Volume17
Issue number1
DOIs
StatePublished - Jan 2 2019

Fingerprint

Helminths
Infection Control
Safety
Antiparasitic Agents
Pharmacokinetics
Therapeutics
Trematode Infections
Cestode Infections
Fenbendazole
Neurocysticercosis
Carbamates
Echinococcosis
Zoonoses
Ruminants
Biological Availability
Half-Life
oxfendazole
Healthy Volunteers
Parasites
Infection

Keywords

  • antiparasitic drugs
  • benzimidazoles
  • cysticercosis
  • helminths
  • hydatid disease
  • Oxfendazole
  • Peru

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology

Cite this

Oxfendazole : a promising agent for the treatment and control of helminth infections in humans. / Gonzalez, Armandoe; Codd, Ellen E.; Horton, John; Garcia, Hector H.; Gilman, Robert H.

In: Expert Review of Anti-Infective Therapy, Vol. 17, No. 1, 02.01.2019, p. 51-56.

Research output: Contribution to journalReview article

@article{ad0a2c0d35994bc3bf49367971eb8c1f,
title = "Oxfendazole: a promising agent for the treatment and control of helminth infections in humans",
abstract = "Introduction: Oxfendazole (methyl [5-(phenylsulphinyl)-1H benzimidazole-2-yl] carbamate) has a particularly long metabolic half-life in ruminants, and its metabolite fenbendazole also has anthelminthic action. A very limited number of drugs are available for the treatment of some zoonotic helminth infections, such as neurocysticercosis and echinococcosis. More recent work has expanded oxfendazole’s nonclinical safety profile and demonstrated its safety and bioavailability in healthy human volunteers, thus advancing the possibility of a new and greatly needed option for antiparasitic treatment of geohelminths and tissue parasites. Areas covered: The present article reviews evidence supporting the safety and efficacy of oxfendazole against both gut and tissue dwelling helminths in animals, as well as more recent safety and pharmacokinetic data supporting its potential for use in human parasitoses. Expert commentary: The pharmacokinetics, safety, and wide spectrum of efficacy of oxfendazole are consistently demonstrated in intestinal helminth infections of animals as well as in tissue dwelling larval cestode and trematode infections in diverse animal species. Now supported by first-in-human safety and pharmacokinetic data, oxfendazole becomes a promising alternative to the limited portfolio of antiparasitic drugs available to treat helminthic diseases of humans.",
keywords = "antiparasitic drugs, benzimidazoles, cysticercosis, helminths, hydatid disease, Oxfendazole, Peru",
author = "Armandoe Gonzalez and Codd, {Ellen E.} and John Horton and Garcia, {Hector H.} and Gilman, {Robert H}",
year = "2019",
month = "1",
day = "2",
doi = "10.1080/14787210.2018.1555241",
language = "English (US)",
volume = "17",
pages = "51--56",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Oxfendazole

T2 - a promising agent for the treatment and control of helminth infections in humans

AU - Gonzalez, Armandoe

AU - Codd, Ellen E.

AU - Horton, John

AU - Garcia, Hector H.

AU - Gilman, Robert H

PY - 2019/1/2

Y1 - 2019/1/2

N2 - Introduction: Oxfendazole (methyl [5-(phenylsulphinyl)-1H benzimidazole-2-yl] carbamate) has a particularly long metabolic half-life in ruminants, and its metabolite fenbendazole also has anthelminthic action. A very limited number of drugs are available for the treatment of some zoonotic helminth infections, such as neurocysticercosis and echinococcosis. More recent work has expanded oxfendazole’s nonclinical safety profile and demonstrated its safety and bioavailability in healthy human volunteers, thus advancing the possibility of a new and greatly needed option for antiparasitic treatment of geohelminths and tissue parasites. Areas covered: The present article reviews evidence supporting the safety and efficacy of oxfendazole against both gut and tissue dwelling helminths in animals, as well as more recent safety and pharmacokinetic data supporting its potential for use in human parasitoses. Expert commentary: The pharmacokinetics, safety, and wide spectrum of efficacy of oxfendazole are consistently demonstrated in intestinal helminth infections of animals as well as in tissue dwelling larval cestode and trematode infections in diverse animal species. Now supported by first-in-human safety and pharmacokinetic data, oxfendazole becomes a promising alternative to the limited portfolio of antiparasitic drugs available to treat helminthic diseases of humans.

AB - Introduction: Oxfendazole (methyl [5-(phenylsulphinyl)-1H benzimidazole-2-yl] carbamate) has a particularly long metabolic half-life in ruminants, and its metabolite fenbendazole also has anthelminthic action. A very limited number of drugs are available for the treatment of some zoonotic helminth infections, such as neurocysticercosis and echinococcosis. More recent work has expanded oxfendazole’s nonclinical safety profile and demonstrated its safety and bioavailability in healthy human volunteers, thus advancing the possibility of a new and greatly needed option for antiparasitic treatment of geohelminths and tissue parasites. Areas covered: The present article reviews evidence supporting the safety and efficacy of oxfendazole against both gut and tissue dwelling helminths in animals, as well as more recent safety and pharmacokinetic data supporting its potential for use in human parasitoses. Expert commentary: The pharmacokinetics, safety, and wide spectrum of efficacy of oxfendazole are consistently demonstrated in intestinal helminth infections of animals as well as in tissue dwelling larval cestode and trematode infections in diverse animal species. Now supported by first-in-human safety and pharmacokinetic data, oxfendazole becomes a promising alternative to the limited portfolio of antiparasitic drugs available to treat helminthic diseases of humans.

KW - antiparasitic drugs

KW - benzimidazoles

KW - cysticercosis

KW - helminths

KW - hydatid disease

KW - Oxfendazole

KW - Peru

UR - http://www.scopus.com/inward/record.url?scp=85059093877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059093877&partnerID=8YFLogxK

U2 - 10.1080/14787210.2018.1555241

DO - 10.1080/14787210.2018.1555241

M3 - Review article

C2 - 30501436

AN - SCOPUS:85059093877

VL - 17

SP - 51

EP - 56

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 1

ER -